This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Genta Takes Another Stab

As Joan indicated, Genta is taking a different, more targeted approach this time around. After digging around in the old phase III study, Genta says it found a subset of melanoma patients with low levels of LDH, a blood enzyme, who appeared to live longer after treatment with Genasense. Conversely, patients with elevated levels of LDH were not helped at all by Genasense.

It's widely believed that melanoma patients with elevated LDH levels tend to have a worse disease prognosis, including shorter survival times.

Genta dug even deeper into these Genasense patients with lower LDH levels, eventually separating them into narrower subgroups defined by their specific LDH levels. What the company found was that patients with "low normal" LDH seemed to survive the longest after treatment with Genasense.

If there's a scientific rationale for why this is true, I didn't hear Warrell discuss it Wednesday. But the company decided to conduct a second, phase III study of Genasense, this time enrolling only patients with "low normal" LDH levels.

The results of that study -- dubbed Agenda -- should be released in the fourth quarter.

If the Genasense trial is a success, Genta will displace Vanda Pharmaceuticals (VNDA - Get Report) as the most shocking, long shot of long shots winner in biotech this year.

After all, Warrell is betting his company's survival on a pivotal study whose hypothesis was derived from a subgroup of a subgroup of a previously failed study. In other words, Genta data-mined a data-mined subset. Stunts like that are never supposed to work in biotech!
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AGEN $5.13 6.88%
ARNA $2.13 0.47%
OPXA $4.09 5.68%
OSIR $10.28 -1.72%
VVUS $1.36 2.26%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs